CERECOR INC. (NASDAQ:CERC) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
CERECOR INC. (NASDAQ:CERC) Files An 8-K Entry into a Material Definitive Agreement
The disclosures set forth in Item 1.01 of the Original 8-K are incorporated into this Amendment No. 1 by reference without changes.
Item 3.02. Unregistered Sales of Equity Securities.
The disclosures set forth in Item 3.02 of the Original 8-K are incorporated into this Amendment No. 1 by reference without changes.
Item 7.01. Regulation FD Disclosure.
The disclosures set forth in Item 7.01 of the Original 8-K are incorporated into this Amendment No. 1 by reference without changes.
Item 9.01. Financial Statements and Exhibits.
>(d) Exhibits
Cerecor Inc. Exhibit
EX-2.1 2 ex-21agreementandplanofmer.htm EXHIBIT 2.1 Exhibit Exhibit 2.1AGREEMENT AND PLAN OF MERGER AND REORGANIZATIONBy and AmongCERECOR INC.GENIE MERGER SUB,…
To view the full exhibit click
EX-2.1 2 ex-21agreementandplanofmer.htm EXHIBIT 2.1 Exhibit Exhibit 2.1AGREEMENT AND PLAN OF MERGER AND REORGANIZATIONBy and AmongCERECOR INC.GENIE MERGER SUB,…
To view the full exhibit click
here
About CERECOR INC. (NASDAQ:CERC)
Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.